Role of 5-HT2A and 5-HT2B/2C receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors

Lance R. McMahon, Kathryn Cunningham

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Dysfunction of monoamine neurotransmission seems to contribute to such pathopsychological states as depression, schizophrenia, and drug abuse. The present study examined the effects of the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SSRI) and antidepressant fluvoxamine on locomotor activity in rats following administration of the catecholamine reuptake inhibitor mazindol. Mazindol (1 mg/kg) did not alter locomotor activity; whereas, fluvoxamine (20 mg/kg) given alone induced a brief period of hypomotility. Hyperactivity was elicited in a dose-related manner when fluvoxamine (5-20 mg/kg) was combined with mazindol (1 mg/kg). The hyperactivity elicited by fluvoxamine (20 mg/kg) plus mazindol (1 mg/kg) was significantly attenuated by the 5-HT2A receptor antagonist M100907 (2 mg/kg) and potentiated by the 5-HT2B/2C receptor antagonist SB 206553 (2 mg/kg). Neither antagonist significantly altered basal activity. The hyperactivity evoked by the combination of fluvoxamine and mazindol seems to be mediated in part by 5-HT2A receptors; whereas, 5-HT2B/2C receptors may serve to limit this effect. Thus, the balance of activation between 5-HT2A and 5-HT2B/2C receptors seems to contribute to the expression of locomotor hyperactivity evoked via combination of a 5-HT and a catecholamine reuptake inhibitor. A disruption in this balance may contribute to the expression of affective disorders, schizophrenia, and drug abuse.

Original languageEnglish (US)
Pages (from-to)319-329
Number of pages11
JournalNeuropsychopharmacology
Volume24
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Receptor, Serotonin, 5-HT2B
Mazindol
Fluvoxamine
Serotonin Uptake Inhibitors
Catecholamines
Serotonin
Receptor, Serotonin, 5-HT2A
Locomotion
Substance-Related Disorders
Schizophrenia
Serotonin 5-HT2 Receptor Antagonists
Mood Disorders
Synaptic Transmission
Antidepressive Agents
Depression

Keywords

  • 5-HT Receptors
  • 5-HT Receptors
  • Dopamine
  • Locomotor activity
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{21fb3662e68f4e13b4f761e90f7b982f,
title = "Role of 5-HT2A and 5-HT2B/2C receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors",
abstract = "Dysfunction of monoamine neurotransmission seems to contribute to such pathopsychological states as depression, schizophrenia, and drug abuse. The present study examined the effects of the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SSRI) and antidepressant fluvoxamine on locomotor activity in rats following administration of the catecholamine reuptake inhibitor mazindol. Mazindol (1 mg/kg) did not alter locomotor activity; whereas, fluvoxamine (20 mg/kg) given alone induced a brief period of hypomotility. Hyperactivity was elicited in a dose-related manner when fluvoxamine (5-20 mg/kg) was combined with mazindol (1 mg/kg). The hyperactivity elicited by fluvoxamine (20 mg/kg) plus mazindol (1 mg/kg) was significantly attenuated by the 5-HT2A receptor antagonist M100907 (2 mg/kg) and potentiated by the 5-HT2B/2C receptor antagonist SB 206553 (2 mg/kg). Neither antagonist significantly altered basal activity. The hyperactivity evoked by the combination of fluvoxamine and mazindol seems to be mediated in part by 5-HT2A receptors; whereas, 5-HT2B/2C receptors may serve to limit this effect. Thus, the balance of activation between 5-HT2A and 5-HT2B/2C receptors seems to contribute to the expression of locomotor hyperactivity evoked via combination of a 5-HT and a catecholamine reuptake inhibitor. A disruption in this balance may contribute to the expression of affective disorders, schizophrenia, and drug abuse.",
keywords = "5-HT Receptors, 5-HT Receptors, Dopamine, Locomotor activity, Serotonin",
author = "McMahon, {Lance R.} and Kathryn Cunningham",
year = "2001",
doi = "10.1016/S0893-133X(00)00206-2",
language = "English (US)",
volume = "24",
pages = "319--329",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Role of 5-HT2A and 5-HT2B/2C receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors

AU - McMahon, Lance R.

AU - Cunningham, Kathryn

PY - 2001

Y1 - 2001

N2 - Dysfunction of monoamine neurotransmission seems to contribute to such pathopsychological states as depression, schizophrenia, and drug abuse. The present study examined the effects of the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SSRI) and antidepressant fluvoxamine on locomotor activity in rats following administration of the catecholamine reuptake inhibitor mazindol. Mazindol (1 mg/kg) did not alter locomotor activity; whereas, fluvoxamine (20 mg/kg) given alone induced a brief period of hypomotility. Hyperactivity was elicited in a dose-related manner when fluvoxamine (5-20 mg/kg) was combined with mazindol (1 mg/kg). The hyperactivity elicited by fluvoxamine (20 mg/kg) plus mazindol (1 mg/kg) was significantly attenuated by the 5-HT2A receptor antagonist M100907 (2 mg/kg) and potentiated by the 5-HT2B/2C receptor antagonist SB 206553 (2 mg/kg). Neither antagonist significantly altered basal activity. The hyperactivity evoked by the combination of fluvoxamine and mazindol seems to be mediated in part by 5-HT2A receptors; whereas, 5-HT2B/2C receptors may serve to limit this effect. Thus, the balance of activation between 5-HT2A and 5-HT2B/2C receptors seems to contribute to the expression of locomotor hyperactivity evoked via combination of a 5-HT and a catecholamine reuptake inhibitor. A disruption in this balance may contribute to the expression of affective disorders, schizophrenia, and drug abuse.

AB - Dysfunction of monoamine neurotransmission seems to contribute to such pathopsychological states as depression, schizophrenia, and drug abuse. The present study examined the effects of the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SSRI) and antidepressant fluvoxamine on locomotor activity in rats following administration of the catecholamine reuptake inhibitor mazindol. Mazindol (1 mg/kg) did not alter locomotor activity; whereas, fluvoxamine (20 mg/kg) given alone induced a brief period of hypomotility. Hyperactivity was elicited in a dose-related manner when fluvoxamine (5-20 mg/kg) was combined with mazindol (1 mg/kg). The hyperactivity elicited by fluvoxamine (20 mg/kg) plus mazindol (1 mg/kg) was significantly attenuated by the 5-HT2A receptor antagonist M100907 (2 mg/kg) and potentiated by the 5-HT2B/2C receptor antagonist SB 206553 (2 mg/kg). Neither antagonist significantly altered basal activity. The hyperactivity evoked by the combination of fluvoxamine and mazindol seems to be mediated in part by 5-HT2A receptors; whereas, 5-HT2B/2C receptors may serve to limit this effect. Thus, the balance of activation between 5-HT2A and 5-HT2B/2C receptors seems to contribute to the expression of locomotor hyperactivity evoked via combination of a 5-HT and a catecholamine reuptake inhibitor. A disruption in this balance may contribute to the expression of affective disorders, schizophrenia, and drug abuse.

KW - 5-HT Receptors

KW - 5-HT Receptors

KW - Dopamine

KW - Locomotor activity

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0035130648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035130648&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(00)00206-2

DO - 10.1016/S0893-133X(00)00206-2

M3 - Article

VL - 24

SP - 319

EP - 329

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -